Insights on the Global Biological/Monoclonal Antibodies Market Analysis 2019 -

DUBLIN--()--The "Global Biological Market/Monoclonal Antibodies Market Analysis 2019" report has been added to's offering.

The Monoclonal Antibodies market is expected to reach $183.35 billion by 2026 growing at a CAGR of 8.3% during 2018 to 2026. Monoclonal is a class of antibodies with identical offspring of a hybridoma. These are derived by cell division from a single parent cell. Monoclonal antibodies are used in the diagnosis of leukemia and more recently in the treatment of malignancies.

Factors such as constant innovation in drug development and discovery, increased need for personalized medicine, and growing R&D activities in genomics are driving the market growth. Though, the high cost of antibodies restrains the market growth. Moreover, the high rate of adoption of therapeutic antibodies and favourable regulatory policies are the opportunities for the monoclonal antibodies market.

Based on source type, the humanized segment is going to have a lucrative growth during the forecast period, owing to its extensive adoption in the treatment of various diseases including cancer, inflammatory, and autoimmune diseases.

The key vendors mentioned are Abbott Laboratories, GlaxoSmithKline Plc, Pfizer , Novartis International, Merck & Co Inc, Johnson & Johnson, Eli Lilly, Amgen Inc, Daiichi Sankyo, AstraZeneca Plc, Thermo Fisher Scientific, Biogen Idec Inc, Mylan N.V, Bayer AG, F.Hoffman-La Roche Ltd, and Bristol Myers Squibb.

Key Questions Answered in this Report:

  • How this market evolved since the year 2016
  • Market size estimations, forecasts and CAGR for all the segments presented in the scope
  • Key Market Developments and financials of the key players
  • Opportunity Analysis for the new entrants
  • SWOT Analysis of the key players
  • Fastest growing markets analysed during the forecast period

Key Topics Covered:

1 Market Synopsis

2 Research Outline

2.1 Research Snapshot

2.2 Research Methodology

2.3 Research Sources

2.3.1 Primary Research Sources

2.3.2 Secondary Research Sources

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Monoclonal Antibodies Market, By Source Type

5.1 Introduction

5.2 Human

5.3 Humanized

5.4 Recombinant

5.5 Chimeric

5.6 Murine

6 Global Monoclonal Antibodies Market, By Production Type

6.1 Introduction

6.2 In Vivo

6.3 In Vitro

7 Global Monoclonal Antibodies Market, By Indication

7.1 Introduction

7.2 Hematological Disorders

7.3 Autoimmune Diseases

7.4 Cancer

7.5 Infectious Diseases

7.6 Neurology

7.7 Cardiovascular

7.8 Microbial Diseases

7.9 Inflammatory Diseases

7.10 Respiratory Diseases

8 Global Monoclonal Antibodies Market, By Application

8.1 Introduction

8.2 Analytical & Chemical Uses

8.3 Therapeutic

8.4 Diagnostic

9 Global Monoclonal Antibodies Market, By End User

9.1 Introduction

9.2 Research Institutes

9.3 Hospitals & Clinics

10 Global Monoclonal Antibodies Market, By Geography

10.1 North America

10.2 Europe

10.3 Asia Pacific

10.4 South America

10.5 Middle East & Africa

11 Strategic Benchmarking

12 Vendors Landscape

12.1 Abbott Laboratories

12.2 GlaxoSmithKline Plc

12.3 Pfizer

12.4 Novartis International

12.5 Merck & Co Inc

12.6 Johnson & Johnson

12.7 Eli Lilly

12.8 Amgen Inc

12.9 Daiichi Sankyo

12.10 AstraZeneca Plc

12.11 Thermo Fisher Scientific

12.12 Biogen Idec Inc

12.13 Mylan N.V.

12.14 Bayer AG

12.15 F.Hoffman-La Roche Ltd

12.16 Bristol Myers Squibb

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900